CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $38.01M, above the global median of $16.24M
- FinancialsAltman Z-Score 3.16: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
719.11MEUR840.10M · vs all stocks (USD)
Trailing P/E
101.35xvs Biotechnology peers
Revenue (TTM)
316.39MUSD369.62M · vs all stocks (USD)
Profit Margin
2.54%vs Biotechnology peers
Beta
0.0620xvs all stocks
52-Week Change
-13.24%vs all stocks
Market Capitalization
719.11MEUR840.10M · vs all stocks (USD)
Enterprise Value
577.40MEUR674.55M · vs all stocks (USD)
Trailing P/E
101.35xvs Biotechnology peers
Forward P/E
46.57xvs Biotechnology peers
Price to Sales (TTM)
1.96xvs Biotechnology peers
Price to Book (MRQ)
3.07xvs Biotechnology peers
Enterprise to Revenue
1.82xvs Biotechnology peers
Enterprise to EBITDA
20.34xvs Biotechnology peers
Gross Margin
83.88%vs Biotechnology peers
Profit Margin
2.54%vs Biotechnology peers
Operating Margin
1.46%vs Biotechnology peers
Return on Assets (TTM)
3.47%vs Biotechnology peers
Return on Equity (TTM)
3.65%vs Biotechnology peers
Revenue (TTM)
316.39MUSD369.62M · vs all stocks (USD)
Revenue per Share (TTM)
0.5220USDUpdated Aug 22, 2026Quarterly Revenue Growth
-3.20%vs Biotechnology peers
Gross Profit (TTM)
273.75MUSD319.81M · vs all stocks (USD)
EBITDA (TTM)
42.65MUSD49.82M · vs all stocks (USD)
Net Income (TTM)
8.03MUSD9.38M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-65.10%vs Biotechnology peers
Operating Cash Flow (TTM)
30.24MUSD35.33M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
32.54MUSD38.01M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00EURUpdated Aug 22, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
0.00USDFY2025 · Dec 31, 2025Revenue
376.13MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
45.50MUSDFY2025 · Dec 31, 2025Gross Profit
330.63MUSDFY2025 · Dec 31, 2025Operating Income
20.88MUSDvs all stocks (USD)
Pre-tax Income
12.85MUSDFY2025 · Dec 31, 2025Income Tax Expense
10.31MUSDFY2025 · Dec 31, 2025Net Income
2.54MUSDFY2025 · Dec 31, 2025EBIT
23.57MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
36.28MUSDFY2025 · Dec 31, 2025Research & Development
100.37MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
117.44MUSDFY2025 · Dec 31, 2025Other Operating Expenses
82.74MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.18MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
10.72MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.0040USDFY2025 · Dec 31, 2025EPS (Diluted)
0.0040USDFY2025 · Dec 31, 2025Basic Shares Outstanding
688.77MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
688.77MSharesFY2025 · Dec 31, 2025Minority Interests (P&L)
313.00KUSDFY2025 · Dec 31, 2025Operating Cash Flow
47.47MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
145.31MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
12.85MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
11.22MUSDFY2025 · Dec 31, 2025Stock-based Compensation
13.77MUSDFY2025 · Dec 31, 2025Other Non-cash Items
13.38MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-3.35MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-386.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-6.00KUSDFY2025 · Dec 31, 2025Net Acquisitions
-58.22MUSDFY2025 · Dec 31, 2025Purchase of Investments
-2.00KUSDFY2025 · Dec 31, 2025Sale of Investments
85.22MUSDFY2025 · Dec 31, 2025Other Investing Activity
-1.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
27.01MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-4.25MUSDFY2025 · Dec 31, 2025Common Dividends Paid
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-7.88MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-12.12MUSDFY2025 · Dec 31, 2025Shares Outstanding
707.78MSharesUpdated Aug 22, 2026Float Shares
696.57MSharesUpdated Aug 22, 2026% Held by Insiders
1.95%vs all stocks
% Held by Institutions
23.15%vs all stocks
Total Cash (MRQ)
136.65MUSD159.64M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.2240USDUpdated Aug 22, 2026Total Debt (MRQ)
97.81MUSD114.27M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4189xvs Biotechnology peers
Current Ratio (MRQ)
3.01xvs Biotechnology peers
Book Value per Share (MRQ)
0.3305USDUpdated Aug 22, 2026Total Assets
499.96MUSDvs all stocks (USD)
Total Current Assets
299.47MUSDFY2025 · Dec 31, 2025Total Liabilities
222.86MUSDFY2025 · Dec 31, 2025Total Non-current Assets
200.50MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
107.07MUSDFY2025 · Dec 31, 2025Total Current Liabilities
115.79MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
145.31MUSDFY2025 · Dec 31, 2025Other Short-term Investments
33.80MUSDFY2025 · Dec 31, 2025Accounts Receivable
41.77MUSDFY2025 · Dec 31, 2025Inventory
64.90MUSDFY2025 · Dec 31, 2025Accounts Payable
8.54MUSDFY2025 · Dec 31, 2025Short-term Debt
8.71MUSDFY2025 · Dec 31, 2025Other Current Liabilities
-1.00KUSDFY2025 · Dec 31, 2025Long-term Debt
107.07MUSDFY2025 · Dec 31, 2025Common Stock (Book)
8.01MUSDFY2025 · Dec 31, 2025Retained Earnings
-272.98MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
277.10MUSDvs all stocks (USD)
52-Week Low
0.8340EURUpdated Aug 22, 202652-Week High
1.82EURUpdated Aug 22, 202652-Week Change
-13.24%vs all stocks
Beta
0.0620xvs all stocks
50-Day MA
1.10EURUpdated Aug 22, 2026200-Day MA
1.32EURUpdated Aug 22, 2026Avg 10-Day Volume
8.75MSharesUpdated Aug 22, 2026Avg 30-Day Volume
11.36MSharesUpdated Aug 22, 2026Diluted EPS (TTM)
0.0100USDUpdated Aug 22, 2026Other Income / Expense
704.00KUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.84Profit Margin: 0.03
Financial Health
Altman Z-Score 3.16: safe zoneNotable
Altman Z-Score: 3.16
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $38.01M, above the global median of $16.24MNotable
Levered free cash flow (USD): 38,009,554.06Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
R&G Pharmastudies Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Anhui Hongyu Wuzhou Medica Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Genfit S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Chengdu Shengnuo Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shouyao Holdings Beijing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Gansu Longshenrongfa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
HK inno.N Corporation
Tier 1ProductionApproval-Gated PipelineRule
Beijing Chunlizhengda Medical Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Luoxin Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Solid Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Sk Biopharmaceuticals Co., Ltd.
3 interpretationsRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
Kalekim Kimyevi Maddeler Sanayi ve Ticaret A.Ş.
3 interpretationsRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
Xiamen Amoytop Biotech Co., Ltd.
3 interpretationsRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated